Division of Gastroenterology and Hepatology, University of Michigan, MI, USA
Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
BMJ. 2018 Jul 18;362:k2817. doi: 10.1136/bmj.k2817.
To describe liver disease related mortality in the United States during 1999-2016 by age group, sex, race, cause of liver disease, and geographic region.
Observational cohort study.
Death certificate data from the Vital Statistics Cooperative, and population data from the US Census Bureau compiled by the Center for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (1999-2016).
US residents.
Deaths from cirrhosis and hepatocellular carcinoma, with trends evaluated using joinpoint regression.
From 1999 to 2016 in the US annual deaths from cirrhosis increased by 65%, to 34 174, while annual deaths from hepatocellular carcinoma doubled to 11 073. Only one subgroup-Asians and Pacific Islanders-experienced an improvement in mortality from hepatocellular carcinoma: the death rate decreased by 2.7% (95% confidence interval 2.2% to 3.3%, P<0.001) per year. Annual increases in cirrhosis related mortality were most pronounced for Native Americans (designated as "American Indians" in the census database) (4.0%, 2.2% to 5.7%, P=0.002). The age adjusted death rate due to hepatocellular carcinoma increased annually by 2.1% (1.9% to 2.3%, P<0.001); deaths due to cirrhosis began increasing in 2009 through 2016 by 3.4% (3.1% to 3.8%, P<0.001). During 2009-16 people aged 25-34 years experienced the highest average annual increase in cirrhosis related mortality (10.5%, 8.9% to 12.2%, P<0.001), driven entirely by alcohol related liver disease. During this period, mortality due to peritonitis and sepsis in the setting of cirrhosis increased substantially, with respective annual increases of 6.1% (3.9% to 8.2%) and 7.1% (6.1% to 8.4%). Only one state, Maryland, showed improvements in mortality (-1.2%, -1.7% to -0.7% per year), while many, concentrated in the south and west, observed disproportionate annual increases: Kentucky 6.8% (5.1% to 8.5%), New Mexico 6.0% (4.1% to 7.9%), Arkansas 5.7% (3.9% to 7.6%), Indiana 5.0% (3.8% to 6.1%), and Alabama 5.0% (3.2% to 6.8%). No state showed improvements in hepatocellular carcinoma related mortality, while Arizona (5.1%, 3.7% to 6.5%) and Kansas (4.3%, 2.8% to 5.8%) experienced the most severe annual increases.
Mortality due to cirrhosis has been increasing in the US since 2009. Driven by deaths due to alcoholic cirrhosis, people aged 25-34 have experienced the greatest relative increase in mortality. White Americans, Native Americans, and Hispanic Americans experienced the greatest increase in deaths from cirrhosis. Mortality due to cirrhosis is improving in Maryland but worst in Kentucky, New Mexico, and Arkansas. The rapid increase in death rates among young people due to alcohol highlight new challenges for optimal care of patients with preventable liver disease.
描述 1999-2016 年美国按年龄组、性别、种族、肝病病因和地理区域划分的肝病相关死亡率。
观察性队列研究。
来自美国疾病控制与预防中心宽范围在线流行病学研究数据资源中心的生命统计合作的死亡证明数据,以及美国人口普查局的人口数据(1999-2016 年)。
美国居民。
肝硬化和肝细胞癌死亡,采用连接点回归评估趋势。
1999 年至 2016 年,美国肝硬化年死亡率上升 65%,达到 34174 例,而肝细胞癌年死亡率增加了一倍,达到 11073 例。只有一个亚组-亚裔和太平洋岛民-肝细胞癌死亡率有所改善:死亡率每年下降 2.7%(95%置信区间 2.2%至 3.3%,P<0.001)。美国原住民(在人口普查数据库中被指定为“美洲印第安人”)的肝硬化相关死亡率增幅最为显著(4.0%,2.2%至 5.7%,P=0.002)。每年因肝细胞癌导致的年龄调整死亡率增加 2.1%(1.9%至 2.3%,P<0.001);肝硬化死亡从 2009 年开始逐年增加 3.4%(3.1%至 3.8%,P<0.001)。2009-16 年间,年龄在 25-34 岁的人群因肝硬化相关死亡的年平均增长率最高(10.5%,8.9%至 12.2%,P<0.001),这完全是由酒精性肝病引起的。在此期间,与肝硬化相关的腹膜炎和败血症死亡率显著增加,分别为每年增加 6.1%(3.9%至 8.2%)和 7.1%(6.1%至 8.4%)。只有一个州,马里兰州,死亡率有所改善(每年减少 1.2%,-1.7%至-0.7%),而许多州,集中在南部和西部,观察到不成比例的年增长率:肯塔基州 6.8%(5.1%至 8.5%),新墨西哥州 6.0%(4.1%至 7.9%),阿肯色州 5.7%(3.9%至 7.6%),印第安纳州 5.0%(3.8%至 6.1%),亚拉巴马州 5.0%(3.2%至 6.8%)。没有一个州的肝细胞癌相关死亡率有所改善,而亚利桑那州(5.1%,3.7%至 6.5%)和堪萨斯州(4.3%,2.8%至 5.8%)的年增长率最高。
自 2009 年以来,美国的肝硬化死亡率一直在上升。由于酒精性肝硬化导致的死亡,年龄在 25-34 岁的人群的死亡率相对增加最大。美国白人、美国原住民和西班牙裔美国人的肝硬化死亡率增幅最大。马里兰州的肝硬化死亡率在改善,但肯塔基州、新墨西哥州和阿肯色州的死亡率则最差。年轻人因饮酒导致的死亡率快速上升,这对预防可避免的肝病患者的最佳护理提出了新的挑战。